Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
-
Clinical Benefit
Substantial
The actual benefit of BYETTA is substantial.
Clinical Added Value
minor
BYETTA provides a minor improvement in actual benefit (IAB IV) in the management of type-2 diabetes in patients treated with a combination of metformin and hypoglycaemic sulphonylurea who have not achieved adequate blood glucose control at the highest tolerated doses of these treatments.
Listen
